Aceso Life Science Group Ltd. issued a clarification in response to an announcement by the Securities and Futures Commission (SFC) regarding the high concentration of its shareholding in the hands of a limited number of shareholders as of 31 December 2025. The company emphasized that shareholders and prospective investors should exercise extreme caution when dealing in its shares due to the potential for substantial price fluctuations even with small trading volumes. Aceso Life Science Group Ltd. also confirmed that, to the best of its knowledge, it continues to meet the public float requirement, with at least 25% of its issued shares held by the public as of the announcement date. The company noted that certain information was extracted from the SFC announcement and has not been independently verified, advising stakeholders to refer to the SFC announcement for further details.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260113-11989693), on January 13, 2026, and is solely responsible for the information contained therein.